Roche And Genentech Acquire Unlimited Access To Open Monoclonal Technology, Inc.’s Omnirat®
Published: Dec 18, 2013
PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic research for discovery of human therapeutic antibodies, today announced that Genentech, a member of the Roche Group, and Roche (SIX: RO, ROG; OTCQX: RHHBY) will acquire unlimited access to OmniRat® through the purchase of one of OMT’s spinout companies. Following the acquisition, Genentech and Roche will be able to use the platform to generate human therapeutic antibodies for any target and indication. Genentech and Roche also gained the right to further engineer the antibody platform.
Help employers find you! Check out all the jobs and post your resume.